{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:02:14Z","timestamp":1787061734889,"version":"build-2736575974"},"reference-count":21,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologica"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Treatment of exudative age-related macular degeneration (ARMD) has shifted to pro re nata and treat-extend-stop strategies. However, a rational discontinuation strategy is lacking. To develop such a strategy, it is important to determine choroidal neovascularization (CNV) recurrence rates after anti-VEGF treatment is discontinued. Here we report prospective data on persistent and recurrent CNV activity after discontinuation of bevacizumab treatment. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This prospective, single-center clinical trial enrolled 191 patients with exudative ARMD. Patients were randomly assigned to receiving intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year. CNV activity was determined in the 157 patients who completed the 1-year treatment regimen. Patients with inactive CNV were then followed for signs of CNV reactivation. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; After 1 year of treatment, 66 (42%) of the 157 patients still had signs of persistent active CNV. Of the remaining 91 (58%) patients, 61 (67%) needed retreatment for active CNV within the first year after discontinuation of treatment (mean 4.28 \u00b1 0.29 months). CNV was reactivated in 50 (80%) of the 61 patients within 6 months after their final treatment for CNV. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Based on quiescent disease, anti-VEGF therapy was discontinued in 58% of the patients after they received bevacizu\u00admab injections every 4, 6, or 8 weeks for 1 year; 67% showed reactivated CNV within a year after discontinuation. The high reactivation rate of CNV shown in this study should help clinicians to develop rational discontinuation protocols. &lt;b&gt;&lt;i&gt;Trial Registration:&lt;\/i&gt;&lt;\/b&gt; This study is registered as NTR1174 at http:\/\/www.trialregister.nl.<\/jats:p>","DOI":"10.1159\/000514539","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T17:00:34Z","timestamp":1611075634000},"page":"200-207","source":"Crossref","is-referenced-by-count":3,"title":["Reactivation of CNV after Discontinuation of Bevacizumab Treatment of Age-Related Macular Degeneration"],"prefix":"10.1159","volume":"244","author":[{"given":"Sankha","family":"Amarakoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u00a0P.","family":"Martinez-Ciriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seerp","family":"Baarsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.\u00a0Ingeborgh","family":"van\u00a0den\u00a0Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Missotten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.039"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.09.011"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306987"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13356"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001282"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001451"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.013"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.012"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001923"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.07.009"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.01.012"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2019.0158"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-3974-0"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12119"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835fd7dd"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S145732"}],"container-title":["Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:25:33Z","timestamp":1745411133000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000514539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2021,7,6]]}},"URL":"https:\/\/doi.org\/10.1159\/000514539","archive":["Portico"],"relation":{},"ISSN":["0030-3755","1423-0267"],"issn-type":[{"value":"0030-3755","type":"print"},{"value":"1423-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}